Collaborative Agreement with Epic Pharma LLC (Details) - USD ($)	1 Months Ended		9 Months Ended
	Jan. 31, 2016	Jun. 30, 2015	Dec. 31, 2018
Collaborative Arrangement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Revenues recognition milestone method, description			On June 4, 2015, the Company entered into the 2015 Epic License Agreement, which provides for the exclusive right to market, sell and distribute, by Epic of SequestOx™, an abuse deterrent opioid which employs the Company’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for payment of product development and pharmacovigilance costs, sales, and marketing of SequestOx™, and Elite will be responsible for the manufacture of the product. Under the 2015 Epic License Agreement, Epic will pay Elite non-refundable payments totaling $15 million, with such amount representing the cost of an exclusive license to ELI-200, the cost of developing the product and certain filings and a royalty based on an amount equal to 50% of profits derived from net product sales as defined in the 2015 Epic License Agreement. The initial term of the exclusive right to product development sales and distribution is five years (“Epic Exclusivity Period”); the license is renewable upon mutual agreement at the end of the initial term.
Elite received non-refundable payments totaling		$ 5,000,000
Epic License Agreement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Received payments totaling			$ 7,500,000
Non-refundable milestone	$ 2,500,000
License fees based on commercial sales			7,500,000
Non receipt remaining milestone			$ 7,500,000